The interleukin-10 promoter genotype predicts diastolic dysfunction in maintenance hemodialysis patients

Hemodialysis International

Volumn 12, Issue 3, 2008, Pages 352-361

  Kirkpantur, Alper ^a   Kahraman, Serkan ^a   Genctoy, Gultekin ^a   Altun, Bulent ^a   Abali, Gulcan ^a   Arici, Mustafa ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Gene polymorphisms; Hemodialysis; Inflammation; Interleukin 10

Indexed keywords

IL10 PROTEIN, HUMAN; INTERLEUKIN 10;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIASTOLE; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PREDICTION AND FORECASTING; PROMOTER REGION; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; SYSTOLE;

ADULT; AGED; BLOOD PRESSURE; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GENOTYPE; HEART FAILURE, DIASTOLIC; HUMANS; INFLAMMATION; INTERLEUKIN-10; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); REGRESSION ANALYSIS; RENAL DIALYSIS; SYSTOLE;

EID: 55949101305     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00281.x     Document Type: Article

References (50)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis. 1998; 32(Suppl 5):S112-S119.
2. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55:1899-1911.
3. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55:648- 658.
4. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995; 154:882-892.
5. Jeron A, Straub RH, Kaiser T, Riegger GA, Muders F. Systemic immunosupression fails to supress cardiac cytokine induction in pressure overload hypertrophy in rats. Immunobiology. 2002; 205:51-60.
6. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999; 85:e17-e24.
7. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. IL-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999; 19:2823-2825.
8. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukine-10 gene promotor. Eur J Immunogenet. 1997; 24:1-8.
9. Nagueh SF, Kopelen HA, Lim DS, et al. Tissue doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2000; 102:1346- 1350.
10. Daugirdas JT. Second generation logarithmic estimates of single pool variable. Volume Kt/V: An analysis of error. J Am Soc Nephrol. 1993; 4:1205-1213.
11. Bergstrom J, Furst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int. 1993; 44:1048-1057.
12. Chobanian AV, Bakris GL, Black HR, et al. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; national high blood pressure education program coordinating committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.
13. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35:469-476.
14. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation. 1978; 58:1072-1083.
15. Reichek N, Devereux RB. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation. 1981; 65:99- 108.
16. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol. 1987; 59:956-960.
17. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol. 1997; 29:641-647.
18. Hayashi SY, Brodin LA, Alvestrand A, et al. Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. Nephrol Dial Transplant. 2004; 19:1497-1506.
19. Ie EHY, Zietse R. Evaluation of the cardiac function in the dialysis patient: A primer for the non-expert. Nephrol Dial Transplant. 2006; 21:1474-1481.
20. Kramer W, Wizemann V, Lammlein G, et al. Cardiac dysfunction in patients on maintenance hemodialysis: II: Systolic and diastolic properties of the left ventricle assessed by invasive methods. Contrib Nephrol. 1986; 52:110-124.
21. Thomas JD, Weynan AE. Echocardiographic doppler evaluation of left ventricular diastolic function: Physics and physiology. Circulation. 1991; 84:977-990.
22. Garcia MJ, Thomas JD, Klein AL. New doppler echocardiographic applications for the study of the diastolic function. J Am Coll Cardiol. 1998; 32:865-875.
23. Sztajzel J, Ruedin P, Monin C, et al. Effect of altered loading conditions during haemodialysis on left ventricular filling pattern. Eur Heart J. 1993; 14:655-661.
24. Bauer F, Jamal F, Douillet R, et al. Acute changes in load: Effects of myocardial velocities measured by doppler tissue imaging. Arch Mal Coeur Vaiss. 2001; 94:1155-1160.
25. Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin- genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002; 62:949-955.
26. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999; 85:e17-e24.
27. Raisanen-Sokolowski A, Glysing-Jensen T, Russell ME. Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: Insights from IL-10 knockout mice. Am J Pathol. 1998; 153:1491-1500.
28. Von der Thüsen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr_/_ mice. FASEB J. 2001; 15:2730-2732.
29. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001; 104:746-749.
30. Kahraman S, Yilmaz R, Arici M, et al. IL-10 genotype predicts serum levels of adhesion molecules, inflammation and atherosclerosis in hemodialysis patients. J Nephrol. 2006; 19:50-56.
31. Girndt M, Ulrich C, Kaul H, Sester U, Sester M, Köhler H. Uremia-associated immune defect: The IL-10-CRP axis. Kidney Int. 2003; 63(Suppl 84):S76-S79.
32. Wharton BA, Balmer SE, Somers K, Templeton AC. The myocardium in kwashiorkor. Q J Med. 1969; 38:107-116.
33. Sjostrom M, Wretling ML, Karlberg I, Eden E, Lundholm K. Ultrastructural changes and enzyme activities for energy production in hearts concomitant with tumor-associated malnutrition. J Surg Res. 1987; 42:304-313.
34. London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B. Cardiac hypertrophy and arterial alterations in endstage renal disease: Hemodynamic factors. Kidney Int. 1993; 43:S42-S49.
35. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH. Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis. 2003; 41:1016-1025.
36. London GM. Left ventricular hypertrophy: Why does it happen? Nephrol Dial Transplant. 2003; 18(Suppl 8):2-6.
37. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int. 2003; 3(Suppl 84):S88-S93.
38. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int. 1989; 36:286-290.
39. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis. 1997; 29:658-668.
40. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. Am J Kidney Dis. 1997; 30:923-927.
41. Rigaud D, Hassid J, Meulemans A, Poupard AT, Boulier A. A paradoxical increase in resting energy expenditure in malnourished patients near death: The king penguin syndrome. Am J Clin Nutr. 2000; 72:355-360.
42. Smith G, Robinson PH, Fleck A. Serum albumin distribution in early treated anorexia nervosa. Nutrition. 1996; 12:677-684.
43. Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int. 1995; 48:510-516.
44. Kopple JD. Nutritional management of nondialyzed patients with chronic renal failure. In: Kopple JD, Massry SG, eds. Nutritional Management of Renal Disease. 1st ed. Baltimore, Maryland, The Williams & Wilkins Co. 1997; 479-531.
45. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides. 1999; 33:415-424.
46. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr. 2003; 13:15-25.
47. Beutler B, Cerami A. The biology of cachectin/TNF-A primary mediator of host response. Annu Rev Immunol. 1989; 7:625-655.
48. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha, and their specific inhibitors in undialyzed patients with chronic renal failure. Kidney Int. 1994; 45:890-896.
49. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNFalpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters. Nephrol Dial Transplant. 1998; 13:1476-1483.
50. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001; 60:2385- 2391.